Crossref


1. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study

- Mohammad Tasavon Gholamhoseini

- Heidar Sharafi

- Helena HL Borba

- Seyed Moayed Alavian

- Asma Sabermahani

- Behzad Hajarizadeh

3. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

- Saman Mohazzab-Torabi

- Fardin Dolatimehr

- Heidar Sharafi

- Mahdi Safi-Abadi

- Mohammad Saeid Rezaee-Zavareh

- Ehsan Bayatpour

- Hamidreza Karimi-Sari

- Seyed Moayed Alavian

5. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

- Heidar Sharafi

- Bita Behnava

- Alireza Azizi-saraji

- Ali Namvar

- Ali Anvar

- Shima Salimi

- Seyed Moayed Alavian

6. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting

- Heidar Sharafi

- Hossein Poustchi

- Fatemeh Azimian

- Babak Tamadoni

- Rashid Ramezani

- Mohamad Mehdi Gouya

- Mahdi Sheikh

- Farnaz Hashemi

- Mehrzad Tashakorian

- Ramin Alasvand

- Seyed Moayed Alavian

- Shahin Merat

8. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection

- Pooneh Rahimi

- Heidar Sharafi

- Golnaz Bahramali

- FaridehSadat SajadianFard

- Nafiseh Sadat Asadi

- Seyed Moayed Alavian

- Vahid Iranpur Mobarakeh

- Seyedeh Zahra Moravej